Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from COV005: a phase 1b/2, multicenter, double-blind, randomized, placebo-controlled study of primary series AZD1222 (ChAdO...

Descripción completa

Detalles Bibliográficos
Autores principales: Koen, Anthonet L., Izu, Alane, Baillie, Vicky, Kwatra, Gaurav, Cutland, Clare L., Fairlie, Lee, Padayachee, Sherman D., Dheda, Keertan, Barnabas, Shaun L., Bhorat, Qasim Ebrahim, Briner, Carmen, Ahmed, Khatija, Bhikha, Sutika, Bhiman, Jinal N., du Plessis, Jeanine, Esmail, Aliasgar, Horne, Elizea, Hwa, Shi-Hsia, Oommen-Jose, Aylin, Lambe, Teresa, Laubscher, Matt, Malahleha, Mookho, Benade, Gabriella, McKenzie, Shakeel, Oelofse, Suzette, Patel, Faeezah, Pillay, Sureshnee, Rhead, Sarah, Rodel, Hylton, Taoushanis, Carol, Tegally, Houriiyah, Thombrayil, Asha, Villafana, Tonya L., Gilbert, Sarah, Pollard, Andrew J., Madhi, Shabir A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133888/
https://www.ncbi.nlm.nih.gov/pubmed/37149443
http://dx.doi.org/10.1016/j.vaccine.2023.04.058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133888/
https://www.ncbi.nlm.nih.gov/pubmed/37149443
http://dx.doi.org/10.1016/j.vaccine.2023.04.058

Ejemplares similares